Alerts will be sent to your verified email
Verify Email
BAFNAPH
|
Bafna Pharma
|
Kappac Pharma
|
Zim Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-52.11 % | -0.23 % | 7.41 % |
|
5yr average Equity Multiplier
|
3.77 | 1.04 | 1.88 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 0.0 | 0.94 |
|
5yr Avg Net Profit Margin
|
-36.55 % | 0.0 | 4.15 % |
|
Price to Book
|
4.01 | 9.43 | 1.41 |
|
P/E
|
38.69 | 0.0 | 53.96 |
|
5yr Avg Cash Conversion Cycle
|
0.18 Days | 0.0 | 37.07 Days |
|
Inventory Days
|
87.65 Days | 0.0 | 68.72 Days |
|
Days Receivable
|
132.64 Days | 0.0 | 99.71 Days |
|
Days Payable
|
210.48 Days | 0.0 | 143.26 Days |
|
5yr Average Interest Coverage Ratio
|
-5.68 | -2260.1 | 3.96 |
|
5yr Avg ROCE
|
-11.61 % | -0.23 % | 13.52 % |
|
5yr Avg Operating Profit Margin
|
-21.98 % | 0.0 | 12.21 % |
|
5 yr average Debt to Equity
|
1.41 | 0.03 | 0.39 |
|
5yr CAGR Net Profit
|
12.0 % | 51.57 % | 10.7 % |
|
5yr Average Return on Assets
|
-16.11 % | -0.22 % | 4.02 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 0.0 | 33.26 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-15.0 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bafna Pharma
|
Kappac Pharma
|
Zim Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
Product Wise Break-Up
|